Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE Triple-negative breast cancer (TNBC) is defined by a lack of expression of estrogen, progesterone, and HER2 receptors, and genetically most of them fall into the basal subgroup of breast cancer. 18314908 2008
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 GeneticVariation disease BEFREE Triple-negative breast cancer (estrogen receptor-, progesterone receptor-, and HER2-negative) (TNBC) is a high risk breast cancer that lacks specific therapy targeting these proteins. 18950515 2008
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Furthermore, 61 patients with triple-negative breast cancer and 39 patients with estrogen receptor-positive/progesterone receptor-positive breast cancer were selected for exploring the clinical relevance of these identified proteins to human breast cancer metastasis. 18981002 2008
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 Biomarker disease BEFREE Triple-negative breast cancer (ie, those with negative estrogen receptor, progesterone receptor, and HER-2/neu status) was diagnosed in 57.1% of the BRCA1-positive patients, 23.3% of the BRCA2-positive patients, and 13.8% of the BRCA-negative patients. 18779615 2008
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 Biomarker disease BEFREE Triple-negative breast cancer (ie, those with negative estrogen receptor, progesterone receptor, and HER-2/neu status) was diagnosed in 57.1% of the BRCA1-positive patients, 23.3% of the BRCA2-positive patients, and 13.8% of the BRCA-negative patients. 18779615 2008
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Among the intriguing characteristics of triple-negative breast cancer is its association with cancers arising in BRCA1 mutation carriers, in young women and in African-American women. 19008097 2008
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Basal-type, or triple-negative, breast cancer (lacking estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 expression) is a high-risk disease for which no molecular therapies are currently available. 19025652 2008
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 Biomarker disease BEFREE Moreover, BRCA1 testing in triple-negative breast cancer patients resistant to docetaxel-based treatment may help to identify families with germinal mutations without a history of hereditary breast cancer. 18591931 2008
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 Biomarker disease BEFREE Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones. 18197009 2008
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Triple-negative breast cancer has been of great interest to oncologists because these cancers do not benefit from hormonal therapies or treatments targeted against human epidermal growth factor receptor 2 receptors. 18841042 2008
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Triple-negative breast cancer (estrogen receptor-, progesterone receptor-, and HER2-negative) (TNBC) is a high risk breast cancer that lacks specific therapy targeting these proteins. 18950515 2008
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE Basal-type, or triple-negative, breast cancer (lacking estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 expression) is a high-risk disease for which no molecular therapies are currently available. 19025652 2008
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. 17982490 2008
Entrez Id: 4781
Gene Symbol: NFIB
NFIB
0.040 AlteredExpression disease BEFREE In conclusion, we have identified recurrently gained regions characteristic of TNBC, and found that NFIB copy number and expression is increased in TNBC across the data sets. 18314908 2008
Entrez Id: 472
Gene Symbol: ATM
ATM
0.030 Biomarker disease BEFREE The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. 17982490 2008
Entrez Id: 3308
Gene Symbol: HSPA4
HSPA4
0.010 Biomarker disease BEFREE Moreover, the validation study in the second set confirmed that 14-3-3, HSP70, and their combination had high sensitivities and specificities in predicting metastatic potential of triple-negative breast cancer. 18981002 2008
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 AlteredExpression disease BEFREE Among these triple-negative breast cancer cases, 97 (67%) expressed one or more basal cytokeratins and 102 (71%) showed EGFR expression. 19390427 2009
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 Biomarker disease BEFREE When p53 is positive in triple-negative breast cancer, we could expect poor survival, prompting aggressive or alternative treatment. 19304743 2009
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen and progesterone receptor as well as human epidermal growth factor receptor 2. 19901010 2009
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE Five deleterious BRCA1 mutations and one deleterious BRCA2 mutation were identified in the 54 patients with early-onset, triple-negative breast cancer (11%). 19298662 2009
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE The armamentarium of "targeted therapeutics" for triple-negative breast cancer is evolving and includes strategies to inhibit angiogenesis, epidermal growth factor receptor, and other kinases. 19596646 2009
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 AlteredExpression disease BEFREE Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen and progesterone receptor as well as human epidermal growth factor receptor 2. 19901010 2009
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE Triple-negative breast cancer (TNBC) lacking expression of steroid receptors and human epidermal growth factor receptor 2, having chemotherapy as the only therapeutic option, is characterised by early relapses and poor outcome.We investigated intratumoural (i.t.) levels of the pro-angiogenic cytokine vascular endothelial growth factor (VEGF) and survival in patients with TNBC compared with non-TNBC. 19549711 2009
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE Women with early-onset triple-negative breast cancer are candidates for genetic testing for BRCA1, even in the absence of a family history of breast or ovarian cancer. 19298662 2009
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.100 AlteredExpression disease BEFREE Our results show that TNBC have higher i.t.VEGF levels compared with non-TNBC. 19549711 2009